Clinical spectrum and prognostic impact of cancer in critically ill patients with HIV: a multicentre cohort study
Background Both AIDS-defining and non-AIDS-defining cancers (ADC/NADC) predispose people living with HIV (PLHIV) to critical illnesses. The objective of this multicentre study was to investigate the prognostic impact of ADC and NADC in PLHIV admitted to the intensive care unit (ICU). Methods All PLHIV admitted over the 2015–2020 period in 12 university-affiliated ICUs in France were included in the study cohort. The effect of ADC and NADC on in-hospital mortality (primary study endpoint) was measured through logistic regression with augmented backward elimination of potential independent variables. The association between ADC/NADC and treatment limitation decision (TLD) during the ICU stay (secondary study endpoint) was analysed. One-year mortality in patients discharged alive from the index hospital admission (exploratory study endpoint) was compared between those with ADC, NADC or no cancer. Results Amongst the 939 included PLHIV (median age, 52 [43–59] years; combination antiretroviral therapy, 74.4%), 97 (10.3%) and 106 (11.3%) presented with an active NADC (mostly lung and intestinal neoplasms) and an active ADC (predominantly AIDS-defining non-Hodgkin lymphoma), respectively. Inaugural admissions were common. Bacterial sepsis and non-infectious neoplasm-related complications accounted for most of admissions in these subgroups. Hospital mortality was 12.4% in patients without cancer, 30.2% in ADC patients and 45.4% in NADC patients (P < 0.0001). NADC (adjusted odds ratio [aOR], 7.00; 95% confidence interval [CI], 4.07–12.05) and ADC (aOR, 3.11; 95% CI 1.76–5.51) were independently associated with in-hospital death after adjustment on severity and frailty markers. The prevalence of TLD was 8.0% in patients without cancer, 17.9% in ADC patients and 33.0% in NADC patients (P < 0.0001)—organ failures and non-neoplastic comorbidities were less often considered in patients with cancer. One-year mortality in survivors of the index hospital admission was 7.8% in patients without cancer, 17.0% in ADC patients and 33.3% in NADC patients (P < 0.0001). Conclusions NADC and ADC are equally prevalent, stand as a leading argument for TLD, and strongly predict in-hospital death in the current population of PLHIV requiring ICU admission..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Annals of intensive care - 13(2023), 1 vom: 22. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Szychowiak, Piotr [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
© The Author(s) 2023. corrected publication 2024 |
|---|
| doi: |
10.1186/s13613-023-01171-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR052831973 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR052831973 | ||
| 003 | DE-627 | ||
| 005 | 20240216064737.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230823s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13613-023-01171-4 |2 doi | |
| 035 | |a (DE-627)SPR052831973 | ||
| 035 | |a (SPR)s13613-023-01171-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Szychowiak, Piotr |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical spectrum and prognostic impact of cancer in critically ill patients with HIV: a multicentre cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023. corrected publication 2024 | ||
| 520 | |a Background Both AIDS-defining and non-AIDS-defining cancers (ADC/NADC) predispose people living with HIV (PLHIV) to critical illnesses. The objective of this multicentre study was to investigate the prognostic impact of ADC and NADC in PLHIV admitted to the intensive care unit (ICU). Methods All PLHIV admitted over the 2015–2020 period in 12 university-affiliated ICUs in France were included in the study cohort. The effect of ADC and NADC on in-hospital mortality (primary study endpoint) was measured through logistic regression with augmented backward elimination of potential independent variables. The association between ADC/NADC and treatment limitation decision (TLD) during the ICU stay (secondary study endpoint) was analysed. One-year mortality in patients discharged alive from the index hospital admission (exploratory study endpoint) was compared between those with ADC, NADC or no cancer. Results Amongst the 939 included PLHIV (median age, 52 [43–59] years; combination antiretroviral therapy, 74.4%), 97 (10.3%) and 106 (11.3%) presented with an active NADC (mostly lung and intestinal neoplasms) and an active ADC (predominantly AIDS-defining non-Hodgkin lymphoma), respectively. Inaugural admissions were common. Bacterial sepsis and non-infectious neoplasm-related complications accounted for most of admissions in these subgroups. Hospital mortality was 12.4% in patients without cancer, 30.2% in ADC patients and 45.4% in NADC patients (P < 0.0001). NADC (adjusted odds ratio [aOR], 7.00; 95% confidence interval [CI], 4.07–12.05) and ADC (aOR, 3.11; 95% CI 1.76–5.51) were independently associated with in-hospital death after adjustment on severity and frailty markers. The prevalence of TLD was 8.0% in patients without cancer, 17.9% in ADC patients and 33.0% in NADC patients (P < 0.0001)—organ failures and non-neoplastic comorbidities were less often considered in patients with cancer. One-year mortality in survivors of the index hospital admission was 7.8% in patients without cancer, 17.0% in ADC patients and 33.3% in NADC patients (P < 0.0001). Conclusions NADC and ADC are equally prevalent, stand as a leading argument for TLD, and strongly predict in-hospital death in the current population of PLHIV requiring ICU admission. | ||
| 650 | 4 | |a Human immunodeficiency virus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Intensive care unit |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Treatment limitation decision |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Outcome |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Boulain, Thierry |4 aut | |
| 700 | 1 | |a Timsit, Jean-François |4 aut | |
| 700 | 1 | |a Elabbadi, Alexandre |4 aut | |
| 700 | 1 | |a Argaud, Laurent |4 aut | |
| 700 | 1 | |a Ehrmann, Stephan |4 aut | |
| 700 | 1 | |a Issa, Nahema |4 aut | |
| 700 | 1 | |a Canet, Emmanuel |4 aut | |
| 700 | 1 | |a Martino, Frédéric |4 aut | |
| 700 | 1 | |a Bruneel, Fabrice |4 aut | |
| 700 | 1 | |a Quenot, Jean-Pierre |4 aut | |
| 700 | 1 | |a Wallet, Florent |4 aut | |
| 700 | 1 | |a Azoulay, Élie |4 aut | |
| 700 | 1 | |a Barbier, François |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of intensive care |d Heidelberg : Springer, 2011 |g 13(2023), 1 vom: 22. Aug. |w (DE-627)SPR031925561 |w (DE-600)2617094-2 |x 2110-5820 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:1 |g day:22 |g month:08 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13613-023-01171-4 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 1 |b 22 |c 08 | ||